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Are clinical trial data shared sufficiently today? No
The AllTrials campaign asks for all trials to be registered and their results published. Ben Goldacre
says we need the evidence to make informed decisions about medicines. John Castellani (doi:10.
1136/bmj.f1881) says mandatory disclosure could affect patient privacy, stifle discovery, and allow
competitors or unscrupulous actors to use the information
Ben Goldacre Wellcome research fellow in epidemiology
London School of Hygiene and Tropical Medicine
When discussing transparency it is important to be clear on what
is being requested, as obfuscation is sometimes used to avoid
discussing simple fixes. At stake are four levels of information
about trials: (1) knowledge that a trial has been conducted, from
a clinical trials register; (2) a brief summary of a trial’s results,
in an academic journal article or regulatory summary; (3) longer
details about the trial’s methods and results, from a clinical
study report where available; (4) individual patient data. The
AllTrials campaign calls only for the first three to be published.
The status quo is plainly unsatisfactory. The most current
review—with no cherry picking permitted—estimates that
around half of all trials for the treatments being used today have
gone unpublished; and that trials with positive results are twice
as likely to be disseminated.1 This is a problem for both industry
and academic trials.
Although some in industry claim that these problems are in the
past, in reality all supposed fixes have failed. In 2005, journal
editors passed regulations stating that they would publish only
registered trials: the evidence now shows these regulations have
been widely ignored.2 In 2007, US legislation was passed
requiring all trials since 2008 to post results on clinicaltrials.gov
within a year of completion: the best published evidence shows
this law has been ignored by 60-90% of trials.3 If industry
representatives believe these problems have been fixed, they
should present published evidence to support their case, with
methods and results that are available for public scrutiny.
Even if the latest rules on transparency were to be implemented
perfectly—starting from now—they would still do nothing to
improve the evidence base for the treatments we use today,
because they all cover only trials from the past few years. More
than 80% of the medicines prescribed this year were generic,
and came on the market more than a decade ago. We need the
results of trials on these treatments, which are still available,
albeit on paper. It is both practical and reasonable to request
that these documents should be simply scanned, and shared.
The arguments against this level of transparency are conflicted
andmisguided. John Castellani, of the Pharmaceutical Research
and Manufacturers of America (PhRMA), has claimed
previously that it’s enough for regulators alone to see all the
information on trials, and to see it behind closed doors. But this
goes against the fundamental principles of science: we rely on
transparency about methods and results, so that every experiment
can be double checked and critically appraised. Although he
might not realise it, Castellani’s position also exposes patients
to real and unnecessary risks. Many of the most notable recent
problems with medicines—problems with rofecoxib (Vioxx)
and rosiglitazone (Avandia), for example, and problems with
the evidence base for oseltamivir (Tamiflu)—were spotted by
independent academics and doctors, and not by regulators. This
isn’t because regulators are incompetent; on the contrary, they
are highly trained, intelligent, and well motivated. But risks and
benefits can be difficult to detect, and like everything in science,
these problems benefit from many eyes.
For similar reasons, it is peculiar to see industry argue that
information should not be shared simply because there might
be disputes about interpretation: disputed interpretations are
widespread throughout science and medicine, they are normal,
and this open debate is how we get closer to the truth. And
likewise, we do not silence medical scaremongers in the media
by hiding information about trials; if anything, routinely
withholding trial results is more likely to undermine public trust.
Overall, the lack of progress on transparency has been startling.
Some worry that these problems should not be discussed in
public, while we fix them quietly behind closed doors. But the
problem of withheld trial results has been documented since at
least 1986,4 and industry has successfully delayed remedial
efforts for three decades. The latest strategy has been to raise
the spectre of patient privacy.
In February, for example, PhRMA released a colourful statement
that misleadingly suggested that I and the BMJ have somehow
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called for the reckless public release of full individual patient
data sets. They made this claim, despite the head of press
relations at PhRMA already knowing that neither I nor the
AllTrials campaign call for individual patient data to be
published.5 6
The BMJ has recently called for individual patient data to be
made more widely available, in an editorial.7
Was this reckless and unreasonable? I don’t believe so. Where
industry has shared data with researchers, it has been only
piecemeal, and after enormous battles. But in many fields, there
is already a long history of sensible and cautious sharing of
detailed datasets—for example, to conduct individual patient
data meta-analyses. These produce better estimates of treatment
benefits, and improve care for patients, with appropriate concern
for confidentiality. The Early Breast Cancer Trialists
Collaborative Group’s meta-analyses, already published,
represent just one notable example.8 The YODA project at Yale
is looking at best practice for data sharing, as are many other
groups.9What’s more, the EuropeanMedicines Agency (EMA)
has fully committed to sharing individual patient data after 2014,
and are consulting only on the best mechanism to do so.10 These
are reasonable and responsible things to discuss, as evidence
based medicine moves forwards and becomes more effective.
Is patient confidentiality also an issue when clinical study reports
are shared, as AllTrials and I have suggested they should be?
Clinical study reports are long documents—often thousands of
pages—but they are important, because analyses have shown
that the information published in academic journal reports on
clinical trials can be misleading or inaccurate, when compared
with these longer, definitive sources of information.11 12 These
reports certainly do contain some information about
individuals—for example, in narrative descriptions of adverse
events—but such information can easily be removed, or shared
only with named researchers, if this is deemed necessary. Some
industry figures have claimed that removing this material is
either impossible or prohibitively expensive. But in 2010 the
European ombudsman made a ruling of maladministration
against the EMA, for claiming exactly that. The ombudsman
examined the clinical study reports requested from the agency
in detail, and concluded that the administrative burden of
removing patient information, where necessary, was small. The
European ombudsman has also stated clearly that there is no
important commercially confidential information in these
reports—the fact that a drug is not as good as claimed is not, in
itself, something any company can hope to ethically withhold
from doctors and patients.13 Since then, the EMA has released
1.6 million pages of clinical study reports14 under its new
policy.13 Because these documents are so informative—and
because the EMAholds only a small proportion of all the clinical
study reports in existence—alltrials.net is asking for all existing
clinical study reports to be made available, on all medicines
currently in use.
This campaign has rapidly snowballed to become themainstream
position in the United Kingdom. AllTrials is now supported by
more than 50 000 individuals, and 250 organizations, including
more than 100 patient groups, the National Institute for Health
and Care Excellence, academic funders such as the Medical
Research Council and the Wellcome Trust, royal colleges, the
Royal Pharmaceutical Society, the British Pharmacological
Society, and the Faculty of Pharmaceutical Medicine, to name
but a few. Ironically, within 24 hours of PhRMA denouncing
our calls for greater transparency, GlaxoSmithKline—the
world’s fourth largest drug company—signed up as supporters
of alltrials.net. They have committed to do the very thing that
PhRMA says is impossible, and share all clinical study reports
going back to the foundation of the company.
If the transparency we ask for is practical, and reasonable, then
what lies behind the colourful denunciations of PhRMA?
Speaking to policy staff in some signatory organizations, one
worrying theme recurs. We knew that withholding trial data
was common, people have said, and we knew that it harms
patients, but we felt embarrassed to talk about it, because even
raising the issue seemed somehow subversive. This is a worrying
state of affairs, and a testament to the power of aggressive
lobbying by industry. But it is also perhaps a testament to the
capture of key opinion leaders, and the dangers of longstanding
inaction at senior levels in the medical establishment. In the
UK, we have seen the same phenomena during prominent
inquiries into failing hospitals: many senior staff, in numerous
organizations, all saw a problem, but most were too busy—or
too anxious about workplace conflict—to put patients first.
The problem of missing trials is one of the greatest ethical and
practical problems facing medicine today. It also represents a
bizarre paradox: we can spend millions of dollars on a trial,
hoping it is free from bias, trying to detect a modest difference
between two treatment groups; and then at the final moment we
let all those biases and errors back in, by permitting half the
results to disappear. Future generations may well look back at
our tolerating this in amazement, in the same way that we look
back on mediaeval bloodletting. The AllTrials movement is
driving the solution forwards: patients need industry to engage
constructively with this widespread consensus, on the practical
details—urgently—so that we can all move on.
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